CRISPR FTO complexities not going anywhere in wake of Broad Institute victory, says IP chief on the CVC side

Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech

Unlock unlimited access to all IAM content